

REMARKS

Applicants elect the Group III invention. Hence, claim 20 is amended herein and the other claims are cancelled without prejudice or disclaimer. Further prosecution on the merits is awaited.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Respectfully submitted,
GENENTECH, INC.

Date: May 27, 2003

By: Wm Lee

Wendy M. Lee
Reg. No. 40,378
Telephone: (650) 225-1994



09157

PATENT TRADEMARK OFFICE

Version with Markings to Show Changes Made

In the specification:

Paragraph beginning at line 12 of page 1 has been amended as follows:

CROSS REFERENCES

This application is a continuation of co-pending U.S. Application Serial No. 09/173,480 filed 14 October 1998 (now U.S. Patent 6,399,746), which is a continuation of U.S. Application Serial No. 08/440,401 filed 12 May 1995 (now U.S. Patent 5,856,110), which is a continuation U.S. Application Serial No. 08/330,161 filed 25 October 1994 (now U.S. Patent 5,834,229), which is a continuation of U.S. Application Serial No. 08/035,430 filed 22 March 1993 (abandoned), which is a continuation of U.S. Application Serial No. 07/705,256 filed 24 May 1991 (abandoned), which applications are incorporated herein by reference and to which applications priority is claimed under 35 USC §120.

In the claims:

Claims 1-19 and 21-38 have been cancelled.

Claim 20 has been amended as follows:

20. (Amended) An isolated antibody that is capable of binding [heregulin 2- β or] heregulin 2- α .